Latest updates on chronic delta hepatitis

Basit Öğe Kaydı
dc.contributor.authorYalcin, Kendal
dc.contributor.authorTuncel, Elif Tugba
dc.contributor.authorGunduz, Feyza
dc.date.accessioned2024-04-24T17:27:41Z
dc.date.available2024-04-24T17:27:41Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe hepatitis D virus was shown for the first time in 1977 by Rizzetto and friends. The HDV genome and the cloning of sequence were made in 1986. HDV is the first animal virus with circular RNA genome which is seen only in plant viruses. HDV is an RNA virus with the known smallest viral genome in animal viruses. It is classified as Deltavirus genius depending on the type of virus by ICTV in 1996. HDV is classified as the sole example of delta virus in this genus. Chronic delta hepatitis is the least common form of chronic viral hepatitis due to hepatotropic viruses. In contrast, the virus is highly pathogenic and can cause serious consequences. Today, prevalance of delta hepatitis has been shown to decrease. However, the delta hepatitis continues to be an important health problem in some parts of the world. In our country, especially in Eastern and Southeastern Anatolia, hepatitis D is a serious and important health problem and still maintains its importance as a health problem. In Turkey, still there is a significant number of patients with HDV infection despite a documented decrease in HDV infection. The recommended treatment for chronic HDV infection in the current guidelines is the treatment with peginterferon alfa given once a week for 48 weeks. Treatment is indicated for patients who has compensated disease with active infection. In patients with advanced form of disease, the expected benefits of the peginterferon must be well balanced against the potential side effects and low response rate. An oral antiviral can be recommended in patients who has high levels of serum HBV DNA. In contrast, the control of HBV infecion does not seem to change the natural history of HDV related disease.en_US
dc.identifier.doi10.5472/MMJsi.2901.10
dc.identifier.endpage54en_US
dc.identifier.issn1309-9469
dc.identifier.scopus2-s2.0-85017389170
dc.identifier.scopusqualityQ4
dc.identifier.startpage50en_US
dc.identifier.urihttps://doi.org/10.5472/MMJsi.2901.10
dc.identifier.urihttps://hdl.handle.net/11468/20137
dc.identifier.volume29en_US
dc.identifier.wosWOS:000430068300008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherMarmara Univ, Fac Medicineen_US
dc.relation.ispartofMarmara Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDelta Hepatitisen_US
dc.subjectTreatmenten_US
dc.subjectPrognosisen_US
dc.titleLatest updates on chronic delta hepatitisen_US
dc.titleLatest updates on chronic delta hepatitis
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu